PET/MRI scans in light-chain amyloid heart disease
Part of Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have confirmed light-chain amyloidosis involving the body or the heart (or be in a specific control group)
- Be able and willing to sign consent
- Be medically stable enough to do heart testing (including lying flat for about 1 hour)
- Be able to safely get PET and heart MRI scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
Hear when a new Amyloidosis, Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.